Document is current

Article History

Received: 26 June 2025

Accepted: 29 January 2026

First Online: 21 March 2026

Declarations

:

: Maggie Harrigan reports receipt of speaking and lecture honorarium from Vertex Pharmaceuticals outside of this research project. Siobhain Mulrennan reports her role as Principal Investigator for Vertex Pharmaceuticals CFTR modulator clinical trials and speaker honorarium from Vertex Pharmaceuticals outside of this research project. Melanie Jessup reports receipt of payment from Vertex Pharmaceuticals for consultancy as part of an independent working group outside of this research project. Kellie Bennett,Phoebe Waters, and Eleni Bacopanos declare no conflicts of interest relevant to the content of this article.

: This study received approval from the University of Western Australia (UWA) Human Research Ethics Committee (Ref: 2021/ET000534).

: No individual data or images shared.

: A full data set of statistical analysis and outputs relating to this paper is held by the corresponding author and can be made available upon request. Not all original data will be shared, in order to protect the privacy of research participants.

: Maggie Harrigan was responsible for the study conceptualisation, investigation, formal analysis, and overall methodology, under the supervision of Dr. Kellie Bennett, Dr. Melanie Jessup, and Dr. Siobhain Mulrennan. Maggie Harrigan produced an original manuscript draft with input from all authors for manuscript revisions. Dr. Phoebe Waters and Dr. Eleni Bacopanos were responsible for data collection regarding physical health. All authors made a significant contribution, are responsible and accountable for the contents of this article, and have approved the final manuscript and choice of journal submission.